Skip to main content
Equibles

Daiwa Securities Group Inc.

Broker-Dealer

Position in SLS — SELLAS Life Sciences Group, Inc.

CIK 1481045 CHIYODA-KU,TOKYO, M0
Back to SLS Full portfolio

Position in SLS

as of Jun 30, 2026 · filed Jul 31, 2026
Position Value
$1,512,900
+$1,503,594 QoQ
Shares Held
102,500
+4559.1% QoQ
Ownership
0.051%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#51
of 192 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in SLS Over Time

Shares Held

Position Value (USD)

Derivatives in SLS

reported options exposure · as of Jun 30, 2026
CallValue
$73,800
CallShares
5,000
PutValue
$1,589,652
PutShares
107,700

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Daiwa Securities Group Inc. holds $185,148,964 across 28 Biotechnology names. SLS ranks #16 (0.8% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 RPRX
Royalty Pharma plc
 749,033 $41,998,280
2 ROIV
Roivant Sciences Ltd.
 1,166,320 $41,276,064
3 VRTX
Vertex Pharmaceuticals Inc / Ma
 71,534 $35,533,083
4 REGN
Regeneron Pharmaceuticals, Inc.
 38,643 $24,095,455
5 ALNY
Alnylam Pharmaceuticals, Inc.
 25,904 $7,797,881
6 RVMD
Revolution Medicines, Inc.
 22,169 $4,151,810
7 JAZZ
Jazz Pharmaceuticals plc
 16,500 $3,976,005
8 INCY
Incyte Corp
 32,675 $3,704,037

All Filings in SLS

Export CSV
5 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $1,589,652 107,700
2026-06-30 $73,800 5,000
2026-06-30 $1,512,900 102,500
2026-03-31 $9,306 2,200
2026-03-31 $9,306 2,200